Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
GRGrace Therapeutics, Inc. logo

Grace Therapeutics, Inc. (GRCE)

NASDAQ Global Market · Currency in USD
$1.93 ▲ +0.02 (+0.78%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.93 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.92
Open
$1.90
Day's Range
$1.89 – $1.95
52 Week Range
$1.79 – $5.18
Volume
47,180
Avg. Volume
181,350
Market Cap
$31.41M
Beta (5Y Monthly)
0.37
PE Ratio (TTM)
--
EPS (TTM)
-$1.24
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$4.00

Profile: Grace Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
5
CEO
Prashant Kohli

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.15 · Revenue est. $1.00M
DateEst.Actual
Aug 13, 2026-$0.13-$0.91Miss
Jun 18, 2026-$0.24-$0.07Beat
Feb 12, 2026-$0.09-$0.14Miss
Nov 13, 2025-$0.12-$0.08Beat
Aug 12, 2025-$0.22-$0.21Beat
Jun 23, 2025-$0.20$0.10Beat

Analyst view

Consensus price target
$4.00 ▲ +107.3%
Range $4.00 – $4.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on GRCE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.